Highlights from: 40th Annual Meeting of the American Society of Clinical Oncology: New Orleans, LA

Clinical Colorectal Cancer

Volumn 4, Issue 3, 2004, Pages 154-158

  Lee, David ^a   Reddy, G Kesava ^a   Ulfers, Amy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; BIOASSAY; CLINICAL TRIAL; COLORECTAL TUMOR; CONFERENCE PAPER; DISEASE FREE SURVIVAL; HUMAN; MEDICAL SOCIETY; MIDDLE AGED; ONCOLOGY; PATHOLOGY;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; SOCIETIES, MEDICAL;

EID: 16544377180     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70112-8     Document Type: Conference Paper

References (21)

1. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
2. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801-3807.
3. Goldberg RM, Sargent DJ, Morton RF, et al. N9741: FOLFOX (oxaliplatin (Oxal)/ 5-fluorouracil (5-FU)/leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from an Intergroup study. Proc Am Soc Clin Oncol 2004; 23:275 (Abstract #3621).
4. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21:1404-1411.
5. Colorectal Cancer Endpoints Workshop Summary. US Food and Drug Administration, 2003. Available at: www.fda.gov/cder/drug/cancer_endpoints/ colonEndpointsSummary.htm. Accessed August 13, 2004.
6. Sargent DJ, Wieand S, Benedetti J, et al. Diseasefree survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. Proc Am Soc Clin Oncol 2004; 23:246 (Abstract #3502).
7. Rodel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21:3098-3104.
8. Bosset JF, Pavy JJ, Hamers HP, et al. Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group. Eur J Cancer 1993; 29A:1406-1410.
9. Cividalli A, Ceciarelli F, Livdi E, et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002; 52:1092-1098.
10. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292.
11. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90:1190-1197.
12. Glynne-Jones R, Sebag-Montefiore D, McDonald A, et al. Preliminary phase II SOCRATES study results: capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 2004; 23:264 (Abstract #3575).
13. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1481.
14. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291-297.
15. Hoff PM, Cassidy J, Schmoll HJ. The evolution of fluoropyrimidine therapy: from intravenous to oral. Oncologist 2001; 6(suppl 4):3-11.
16. Cassidy J, Scheithauer W, McKendrick J, et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. 40th Annual Meeting of the American Society of Clinical Oncology 2004. Late-breaking abstract available at: www.asco.org. Abstract #3509.
17. Feliú J, Escudero P, Losa F, et al. A phase II study of capecitabine (X) in elderly patients (p) as 1st line treatment for patients (pts) with advanced or metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2004; 23:262 (Abstract #3567).
18. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29(suppl 14):38-44.
19. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999; 59:1236-1243.
20. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002; 21:10a (Abstract #35).
21. Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc Am Soc Clin Oncol 2004; 23:248 (Abstract #3511).